250 related articles for article (PubMed ID: 30768836)
1. Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients.
Suliman M; Buckley A; Al Tikriti A; Tan T; le Roux CW; Lessan N; Barakat M
Diabetes Obes Metab; 2019 Jun; 21(6):1498-1501. PubMed ID: 30768836
[TBL] [Abstract][Full Text] [Related]
2. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of High-Dose Liraglutide as an Adjunct for Weight Loss in Patients with Prior Bariatric Surgery.
Rye P; Modi R; Cawsey S; Sharma AM
Obes Surg; 2018 Nov; 28(11):3553-3558. PubMed ID: 30022424
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide: A New Option for the Treatment of Obesity.
Nuffer WA; Trujillo JM
Pharmacotherapy; 2015 Oct; 35(10):926-34. PubMed ID: 26497479
[TBL] [Abstract][Full Text] [Related]
5. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.
O'Neil PM; Aroda VR; Astrup A; Kushner R; Lau DCW; Wadden TA; Brett J; Cancino AP; Wilding JPH;
Diabetes Obes Metab; 2017 Nov; 19(11):1529-1536. PubMed ID: 28386912
[TBL] [Abstract][Full Text] [Related]
6. Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
Tronieri JS; Wadden TA; Walsh OA; Berkowitz RI; Alamuddin N; Gruber K; Leonard S; Chao AM
Metabolism; 2019 Jul; 96():83-91. PubMed ID: 30902750
[TBL] [Abstract][Full Text] [Related]
7. Liraglutide (Saxenda) for weight loss.
Med Lett Drugs Ther; 2015 Jun; 57(1471):89-90. PubMed ID: 26079762
[No Abstract] [Full Text] [Related]
8. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
Lundgren JR; Janus C; Jensen SBK; Juhl CR; Olsen LM; Christensen RM; Svane MS; Bandholm T; Bojsen-Møller KN; Blond MB; Jensen JB; Stallknecht BM; Holst JJ; Madsbad S; Torekov SS
N Engl J Med; 2021 May; 384(18):1719-1730. PubMed ID: 33951361
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide 3.0 mg (Saxenda©) for Weight Loss and Remission of Pre-Diabetes. Real-World Clinical Evaluation of Effectiveness among Patients Awaiting Bariatric Surgery.
Wilmington R; Ardavani A; Simenacz A; Green C; Idris I
Obes Surg; 2024 Jan; 34(1):286-289. PubMed ID: 38012508
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial.
Wadden TA; Tronieri JS; Sugimoto D; Lund MT; Auerbach P; Jensen C; Rubino D
Obesity (Silver Spring); 2020 Mar; 28(3):529-536. PubMed ID: 32090517
[TBL] [Abstract][Full Text] [Related]
11. Use of Weight Loss Medications in Patients after Bariatric Surgery.
Redmond IP; Shukla AP; Aronne LJ
Curr Obes Rep; 2021 Jun; 10(2):81-89. PubMed ID: 33492629
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study.
Gorgojo-Martínez JJ; Basagoiti-Carreño B; Sanz-Velasco A; Serrano-Moreno C; Almodóvar-Ruiz F
Int J Clin Pract; 2019 Nov; 73(11):e13399. PubMed ID: 31397946
[TBL] [Abstract][Full Text] [Related]
13. ▾ Liraglutide for weight management.
Drug Ther Bull; 2017 Jul; 55(7):78-81. PubMed ID: 28701318
[TBL] [Abstract][Full Text] [Related]
14. liraglutide (SAXENDA⁰) and obesit. Still no satisfactory weight loss drugs.
Prescrire Int; 2016 Jan; 25(167):5-8. PubMed ID: 26942248
[TBL] [Abstract][Full Text] [Related]
15. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
Halawi H; Khemani D; Eckert D; O'Neill J; Kadouh H; Grothe K; Clark MM; Burton DD; Vella A; Acosta A; Zinsmeister AR; Camilleri M
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):890-899. PubMed ID: 28958851
[TBL] [Abstract][Full Text] [Related]
16. The Current Role of Liraglutide in the Pharmacotherapy of Obesity.
Christou GA; Katsiki N; Kiortsis DN
Curr Vasc Pharmacol; 2016; 14(2):201-7. PubMed ID: 26074046
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of High-dose Liraglutide 3.0 mg in Patients with Poor Response to Bariatric Surgery: Real-world Experience and Updated Meta-analysis.
Vinciguerra F; Di Stefano C; Baratta R; Pulvirenti A; Mastrandrea G; Piazza L; Guccione F; Navarra G; Frittitta L
Obes Surg; 2024 Feb; 34(2):303-309. PubMed ID: 38183597
[TBL] [Abstract][Full Text] [Related]
18. Obesity Epidemic: Pharmaceutical Weight Loss.
Curry SA
R I Med J (2013); 2017 Mar; 100(2):18-20. PubMed ID: 28246654
[TBL] [Abstract][Full Text] [Related]
19. GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice.
Frikke-Schmidt H; Hultman K; Galaske JW; Jørgensen SB; Myers MG; Seeley RJ
Mol Metab; 2019 Mar; 21():13-21. PubMed ID: 30685336
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
Torekov SS
Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
[No Abstract] [Full Text] [Related]
[Next] [New Search]
